Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 8 clinical trials
Featured trial
The Potential Added Value of Impulse Oscillometry in Asthma Monitoring (AM-IOS)

The goal of this longitudinal observational study is to learn if impulse oscillometry (IOS) has an added value in asthma monitoring in adult asthma patients who are prescribed a change in asthma maintenance therapy. The main questions it aims to answer are:Is there a difference in the change in IOS …

  • 0 views
  • 24 Nov, 2025
  • 1 location
Featured trial
Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma

This project will evaluate the efficacy and safety of the conditioning regimen bortezomib-bendamustine-melphalan (BBM) in combination with autologous hematopoietic stem cell transplantation (ASCT) in relapsed multiple myeloma given from 2011 to 2018 at Uppsala University Hospital. This approach will be retrospectively compared to high dose melphalan (HDM) in the same …

  • 0 views
  • 01 Dec, 2025
  • 2 locations
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Eligible participants will be randomized in a 1:1 ratio to receive one of the following treatment regimens during induction phase:- Arm A: Tiragolumab plus atezolizumab and CE Arm B: Placebo plus atezolizumab and CE Following the induction phase, participants will continue maintenance therapy with either atezolizumab plus tiragolumab (Arm A) …

cancer
solid tumour
measurable disease
small cell lung cancer
extensive stage sclc
  • 0 views
  • 19 Feb, 2024
  • 147 locations
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Combination Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

This phase III trial aims to compare the progression free survival (PFS) and safety of fulvestrant or capecitabine as maintenance therapy after first-line combined chemotherapy in hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer.

cancer
human epidermal growth factor
chromogenic in situ hybridization
cancer chemotherapy
liver metastasis
  • 0 views
  • 19 Feb, 2024
  • 7 locations
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.

cancer
sarcoma
recurrent disease
olaparib
durvalumab
  • 0 views
  • 19 Feb, 2024
  • 95 locations
Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

The purpose of this study is to test if delaying the start of the olaparib until there is a rise in a tumor marker called CA-125 will result in a longer time until the next or different treatment for the patient's cancer. The study will also evaluate how delaying the …

cancer
solid tumour
recurrent ovarian cancer
cancer antigen 125
ovarian cancer
  • 0 views
  • 19 Feb, 2024
  • 1 location
TDLN-sparing RT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

The goal of this clinical trial is to learn if tumor draining lymph nodes-sparing radiotherapy (TDLN-sparing RT) followed by immunotherapy as maintenance therapy works to treat locally advanced esophageal squamous cell cancer in adults.

  • 0 views
  • 12 May, 2025
  • 1 location
A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)

This study is a randomized, national multicenter clinical study which is designed to compare the efficacy of the safety and efficacy of treatment every 3 weeks or 6 weeks in (Non-small-cell-cell cancer, NSCLC) subjects without systematic treatment who used Pembrolizumab after 6 cycles of combined chemotherapy estimated with stable efficacy …

  • 0 views
  • 19 Feb, 2024
  • 1 location